CRMD Stock Analysis: Buy, Sell, or Hold?
CRMD - CorMedix Inc.
$8.28
0.08 (0.98%)
▲
5d:
+7.95%
30d:
+5.21%
90d:
+3.76%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 13, 2026 at $8.24 · last confirmed Aug 18, 2026
Strength: 7.6/10
Get Alerted When CRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CRMD shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CRMD shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CRMD is currently trading at $8.28, which is considered extended relative to its 30-day fair value range of $7.38 to $8.18. From a valuation perspective, the stock is trading at a premium (Forward PE: 138.0) compared to its historical average (31.4). At these levels, the market is pricing in 63.7% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CRMD is in a uptrend. Immediate support is located at $7.10, while resistance sits at $8.98.
Market Sentiment: CRMD scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.40 (+86.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRMD is in a uptrend. Immediate support is located at $7.10, while resistance sits at $8.98.
Market Sentiment: CRMD scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.40 (+86.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.38 -
$8.18
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
23.8%
Protect Your Profits
Holding CRMD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 86.0% below Wall St target ($15.40)
- BEARISH: Market expects 63.7% growth - appears too optimistic based on history
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.38 -
$8.18
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.10
Resistance Level
$8.98
Current Trend
Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
138.00
Wall Street Target
$15.40
(+86.0%)
Revenue Growth (YoY)
156.5%
Earnings Growth (YoY)
6.7%
Profit Margin
40.5%
Valuation Premium vs History
+63.7% premium
PE vs Historical
138.0 vs 31.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+63.7%
(market-implied from PE analysis)
1-Year Target
$12.42
(+50%)
2-Year Target
$18.63
(+125%)
3-Year Target
$27.94
(+238%)
3-Yr Target (if PE normalizes)
(PE: 138→31)
PE COMPRESSION
$6.36
(-23%)
Significant PE compression expected
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 138.0, Growth: -87.7%)
$6.04
(+-27%)
Base:
(SPY PE: 20.1, Growth: -87.7%)
$0.88
(-89%)
Bear:
(PE: 17.0, Growth: -87.7%)
$0.75
(-91%)
📈
Valuation based on Current Earnings
Trailing PE: 3.76 | Current EPS (TTM): $2.18
Bull Case
$4.51
(-46%)
Analyst growth -50.0%, PE expands to 4.1
Base Case
$4.10
(-51%)
Market implied -50.0%, PE stable at 3.8
Bear Case
$5.58
(-33%)
Severe decline -20.0%, PE contracts to 3.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 24, 2026 6:05 PM ET
Data refreshes hourly during market hours. Next update: 7:05 PM
Data refreshes hourly during market hours. Next update: 7:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 38 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
Advanced CRMD Option Strategies
Professional options setups generated by AI based on today's CRMD price and gamma walls.
